The Pentagon moves to take back troops discharged over COVID-19 vaccine refusals
The Pentagon says the military services must again ask troops who were forced out or who voluntarily left the military due to the COVID vaccine whether they want to reenlist.
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect ...
Hosted on MSN4h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Texas AG launches probe into controversial Chinese AI app DeepSeek: ‘Stealing the data of our citizens’
Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...
Pharm Exec5h
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
STAT5h
U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Becker's Hospital Review6h
8 drugs in shortage
Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...
appliedclinicaltrialsonline8h
Updated TALAPRO-2 Trial Data Confirms Talzenna Plus Xtandi Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
Hosted on MSN9h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
The American Journal of Managed Care9h
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...